{"id":"W3088668888","doi":"10.1016/j.annonc.2020.08.2085","title":"691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Astellas Pharma Global Development; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Placebo; Internal medicine; Oncology; Urology; Discontinuation; Hazard ratio; Androgen deprivation therapy; Gynecology; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131003,0.001856751,0.00251504,0.0004347817,0.0005548558,0.0011519,0.001167431,0.001503528,0.02590168],"category_scores_gemma":[0.0009616722,0.0008282504,0.001453289,0.000517057,0.0007184168,0.0007437185,0.0004336073,0.003339653,0.004062246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006508215,"about_ca_system_score_gemma":0.001850654,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001611894,"about_ca_topic_score_gemma":0.006034065,"domain_scores_codex":[0.9996079,0.0002004967,0.000022727,0.00005746919,0.00003214967,0.00007928509],"domain_scores_gemma":[0.9995378,0.0000984396,0.0000765914,0.00003622814,0.00003634982,0.0002145471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9658463,0.00622535,0.0003986984,0.0008711665,0.000912014,0.00004110295,0.00003022169,0.0002210144,0.005085341,0.0001573776,0.004476071,0.01573534],"study_design_scores_gemma":[0.9658324,0.03072268,0.00123197,0.00003138314,0.000301098,0.0000191163,0.000009761819,0.0001171744,0.0002881864,0.00008332349,0.001352059,0.00001085898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.8998522,0.0113754,0.002860904,0.002445707,0.001586135,0.03138686,0.02547791,0.001443799,0.02357115],"genre_scores_gemma":[0.868889,0.008782767,0.01032704,0.007409425,0.001131283,0.0394223,0.0233426,0.0003115655,0.04038401],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.02590168,"threshold_uncertainty_score":0.08664972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07288615058085053,"score_gpt":0.4158688863966084,"score_spread":0.3429827358157578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}